See more : Tianjin Lisheng Pharmaceutical Co.,Ltd. (002393.SZ) Income Statement Analysis – Financial Results
Complete financial analysis of Transgene SA (0OCQ.L) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Transgene SA, a leading company in the Medical – Pharmaceuticals industry within the Healthcare sector.
- G Three Holdings Corporation (3647.T) Income Statement Analysis – Financial Results
- MainStreet Bancshares, Inc. (MNSBP) Income Statement Analysis – Financial Results
- Verde Resources, Inc. (VRDR) Income Statement Analysis – Financial Results
- DigitalBridge Group, Inc. (DBRG-PH) Income Statement Analysis – Financial Results
- Imugene Limited (IMU.AX) Income Statement Analysis – Financial Results
Transgene SA (0OCQ.L)
About Transgene SA
Transgene SA, a biotechnology company, focuses on designing and developing therapeutic vaccines and oncolytic viruses for the treatment of cancer and infectious diseases. It is involved in developing TG4050, a therapeutic vaccine that is in phase I clinical trial for the treatment of ovarian cancer, and human papilloma virus (HPV)-negative head and neck cancers; TG4001, a therapeutic vaccine, which is in phase II clinical trial for the treatment of HPV-positive cancers; TG6002, an oncolytic virus that is in phase I/IIa clinical trial for the treatment of various solid tumors, such as gastrointestinal adenocarcinoma comprising stomach, pancreas, and colon; and BT-001, an oncolytic virus, which is in phase I/II clinical trial for the treatment of solid tumors. The company also develops TG1050, a therapeutic vaccine for the treatment of chronic hepatitis B; and Pexa-Vec, an oncolytic virus for the treatment of solid tumors. It has strategic collaboration agreements with AstraZeneca, Merck KGaA, Pfizer, PersonGen BioTherapeutics, and NEC Corporation; licensing agreements with SillaJen, Ascend BioPharmaceutical, and Valneva; and agreements with Sanofi, BioInvent, and Randox. The company was incorporated in 1979 and is headquartered in Illkirch-Graffenstaden, France. Transgene SA is a subsidiary of TSGH SAS.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1.18M | 3.13M | 9.99M | 2.98M | 6.65M | 1.34M | 2.10M | 2.35M | 1.47M | 2.49M | 3.85M | 3.93M | 14.45M | 14.11M | 11.77M | 13.95M | 28.02M | 5.55M | 2.51M | 2.50M | 2.21M | 1.26M | 4.72M | 4.33M | 11.67M | 6.71M |
| Cost of Revenue | 29.59M | 32.17M | 32.88M | 27.35M | 31.39M | 27.34M | 8.50M | 2.04M | 2.64M | 15.20M | 16.40M | 14.90M | 53.05M | 42.52M | 33.03M | 32.27M | 28.80M | 24.16M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.53M | 1.38M |
| Gross Profit | -28.40M | -29.04M | -22.89M | -24.37M | -24.73M | -26.01M | -6.40M | 309.00K | -1.17M | -12.71M | -12.55M | -10.97M | -38.60M | -28.41M | -21.26M | -18.32M | -780.00K | -18.61M | 2.51M | 2.50M | 2.21M | 1.26M | 4.72M | 4.33M | 10.13M | 5.33M |
| Gross Profit Ratio | -2,398.99% | -929.05% | -229.06% | -817.34% | -371.81% | -1,948.09% | -304.95% | 13.17% | -79.93% | -510.44% | -326.08% | -279.33% | -267.22% | -201.31% | -180.72% | -131.36% | -2.78% | -335.54% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 86.86% | 79.45% |
| Research & Development | 29.59M | 32.17M | 32.88M | 27.35M | 17.56M | 27.35M | 30.36M | 26.42M | 32.14M | 49.82M | 50.06M | 48.68M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 20.01M | 20.26M | 19.08M | 21.06M | 22.52M | 21.81M | 20.86M | 17.93M |
| General & Administrative | 3.82M | 3.22M | 2.59M | 2.32M | 3.43M | 3.50M | 2.40M | 2.20M | 2.70M | 3.60M | 3.20M | 3.60M | 6.23M | 6.30M | 6.15M | 5.26M | 5.75M | 3.93M | 4.17M | 4.27M | 3.55M | 2.93M | 6.89M | 4.31M | 4.68M | 3.40M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 3.82M | 3.22M | 2.59M | 2.32M | 3.43M | 3.50M | 2.40M | 2.20M | 2.70M | 3.60M | 3.20M | 3.60M | 6.23M | 6.30M | 6.15M | 5.26M | 5.75M | 3.93M | 4.17M | 4.27M | 3.55M | 2.93M | 6.89M | 4.31M | 4.68M | 3.40M |
| Other Expenses | -2.18M | -2.14M | -1.74M | -2.35M | 10.88M | 34.64M | 590.00K | 1.51M | 245.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 4.00K | 17.00K | 15.00K | 17.00K | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 31.23M | 33.25M | 33.74M | 27.31M | 31.88M | 28.60M | 30.70M | 26.24M | 29.73M | 44.39M | 45.06M | 46.05M | 6.23M | 6.20M | 6.07M | 3.63M | 6.68M | 3.91M | 24.18M | 24.34M | 22.54M | 23.98M | 29.41M | 26.12M | 27.08M | 22.71M |
| Cost & Expenses | 31.23M | 33.25M | 33.74M | 27.31M | 31.88M | 28.60M | 30.70M | 26.24M | 29.73M | 44.39M | 45.06M | 46.05M | 59.27M | 48.72M | 39.10M | 35.90M | 35.48M | 28.06M | 24.18M | 24.34M | 22.54M | 23.98M | 29.41M | 26.12M | 28.61M | 24.09M |
| Interest Income | 7.72M | 309.00K | 4.20M | 8.02M | 8.16M | 909.00K | 1.56M | 73.00K | 213.00K | 420.00K | 663.00K | 533.00K | 1.43M | 386.00K | 0.00 | 4.01M | 1.98M | 551.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 168.00K | 804.00K | 464.00K | 1.34M | 1.44M | 0.00 | 0.00 | 752.00K | 554.00K | 671.00K | 702.00K | 639.00K | 502.00K | 0.00 | 0.00 | 26.00K | 33.00K | 36.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 170.31K | 0.00 |
| Depreciation & Amortization | 1.59M | 1.67M | 2.51M | 1.77M | 1.83M | 2.21M | 1.91M | 2.04M | 2.64M | 3.04M | 2.91M | 2.76M | 2.74M | 2.41M | 3.76M | 3.66M | 2.31M | 1.59M | 1.42M | 1.45M | 1.43M | 1.45M | 1.81M | 1.91M | -1.53M | -1.38M |
| EBITDA | -27.02M | -28.21M | -23.55M | -20.44M | -22.10M | 2.85M | -29.50M | -20.38M | -34.72M | -37.41M | -38.27M | -39.37M | -40.16M | -32.19M | -25.12M | -18.29M | -5.15M | -20.92M | -20.25M | -20.39M | -19.04M | -21.27M | -22.88M | -19.89M | -37.06M | -16.00M |
| EBITDA Ratio | -2,282.43% | -969.55% | -165.59% | -477.22% | -232.68% | 809.74% | -1,402.91% | -891.77% | -1,854.74% | -1,565.06% | -994.96% | -1,001.22% | -291.35% | -228.12% | -200.38% | -131.13% | -18.37% | -377.26% | -805.37% | -811.48% | -854.71% | -1,561.43% | -484.36% | -459.77% | -132.12% | -238.36% |
| Operating Income | -30.05M | -29.90M | -23.53M | -23.99M | -25.45M | 7.37M | -28.04M | -22.66M | -35.81M | -46.93M | -41.20M | -42.14M | -44.83M | -34.61M | -27.34M | -21.95M | -7.46M | -22.51M | -21.67M | -21.94M | -20.38M | -24.32M | -24.69M | -21.79M | -13.88M | -14.62M |
| Operating Income Ratio | -2,537.75% | -956.62% | -235.41% | -804.86% | -382.65% | 551.91% | -1,336.02% | -966.07% | -2,444.16% | -1,884.82% | -1,070.36% | -1,072.68% | -310.31% | -245.22% | -232.34% | -157.39% | -26.62% | -405.95% | -861.97% | -877.09% | -923.80% | -1,930.40% | -522.59% | -503.91% | -118.98% | -217.81% |
| Total Other Income/Expenses | 1.27M | -2.90M | 4.16M | 6.76M | 6.65M | 36.25M | -4.29M | -1.76M | -2.10M | 5.82M | -1.68M | -1.06M | 1.43M | 386.00K | -12.00K | 3.95M | 1.94M | 483.00K | 489.00K | 1.06M | 1.88M | 2.30M | 1.94M | 2.75M | 1.57M | 3.68M |
| Income Before Tax | -28.78M | -32.80M | -19.54M | -17.23M | -18.80M | 8.03M | -32.27M | -24.18M | -37.91M | -47.73M | -41.93M | -42.73M | -43.40M | -34.22M | 0.00 | -18.00M | -5.52M | -22.03M | -21.18M | -20.88M | -18.37M | -22.03M | -22.75M | -19.04M | -37.04M | -13.70M |
| Income Before Tax Ratio | -2,430.57% | -1,049.39% | -195.50% | -578.03% | -282.68% | 601.20% | -1,537.59% | -1,030.82% | -2,587.65% | -1,916.99% | -1,089.32% | -1,087.81% | -300.44% | -242.48% | 0.00% | -129.04% | -19.70% | -397.24% | -842.52% | -834.67% | -832.59% | -1,748.02% | -481.50% | -440.28% | -317.52% | -204.11% |
| Income Tax Expense | -6.45M | 6.00K | 468.00K | 1.22M | 2.56M | 20.00K | -3.10M | 500.00K | 14.46M | 5.75M | 921.00K | 518.00K | 224.00K | 0.00 | 12.00K | 0.00 | 0.00 | 0.00 | -696.00K | 188.00K | 39.00K | -78.00K | -267.00K | -818.00K | -2.04M | -1.84M |
| Net Income | -22.33M | -32.81M | -20.00M | -18.45M | -21.36M | 8.03M | -32.27M | -25.21M | -46.37M | -48.56M | -42.86M | -43.20M | -43.63M | -34.22M | -27.35M | -18.00M | -5.52M | -22.03M | -20.49M | -20.88M | -18.41M | -21.95M | -22.48M | -18.22M | -35.00M | -11.86M |
| Net Income Ratio | -1,885.81% | -1,049.58% | -200.18% | -618.92% | -321.11% | 601.20% | -1,537.59% | -1,074.47% | -3,165.46% | -1,950.04% | -1,113.48% | -1,099.87% | -301.99% | -242.48% | -232.44% | -129.04% | -19.70% | -397.24% | -814.84% | -834.67% | -834.36% | -1,741.83% | -475.85% | -421.36% | -300.00% | -176.71% |
| EPS | -0.22 | -0.33 | -0.22 | -0.22 | -0.26 | 0.13 | -0.51 | -0.45 | -1.20 | -1.26 | -1.34 | -1.36 | -1.34 | -1.20 | -1.21 | -0.79 | -0.27 | -1.36 | -1.97 | -2.00 | -1.77 | -2.52 | -3.76 | -3.10 | -6.61 | -3.38 |
| EPS Diluted | -0.22 | -0.33 | -0.22 | -0.22 | -0.26 | 0.13 | -0.51 | -0.44 | -1.17 | -1.23 | -1.31 | -1.33 | -1.34 | -1.20 | -1.21 | -0.79 | -0.27 | -1.36 | -1.97 | -2.00 | -1.77 | -2.52 | -3.76 | -3.10 | -5.96 | -3.38 |
| Weighted Avg Shares Out | 100.59M | 99.50M | 91.11M | 83.65M | 83.10M | 61.76M | 63.57M | 56.43M | 38.55M | 38.53M | 31.87M | 31.76M | 32.51M | 28.41M | 22.69M | 22.90M | 20.44M | 16.20M | 10.42M | 10.42M | 10.42M | 8.70M | 5.98M | 5.89M | 5.30M | 3.51M |
| Weighted Avg Shares Out (Dil) | 100.59M | 99.50M | 91.11M | 83.65M | 83.10M | 62.28M | 63.67M | 57.88M | 39.53M | 39.52M | 32.69M | 32.58M | 32.51M | 28.41M | 22.69M | 22.90M | 20.44M | 16.20M | 10.42M | 10.42M | 10.42M | 8.70M | 5.98M | 5.89M | 5.87M | 3.51M |
Source: https://incomestatements.info
Category: Stock Reports